Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jul-Aug;26(4):294-7.
doi: 10.4103/0971-4065.171233.

Karyomegalic interstitial nephropathy following ifosfamide therapy

R Jayasurya  1 , B H Srinivas  2 , M Ponraj  3 , S Haridasan  1 , S Parameswaran  1 , P S Priyamvada  1
Affiliations
Case Reports

Karyomegalic interstitial nephropathy following ifosfamide therapy

R Jayasurya et al. Indian J Nephrol. 2016 Jul-Aug.

Abstract

Ifosfamide (IFO), an alkylating agent used for the management of solid organ tumors, can cause reversible Fanconi's syndrome and acute kidney injury. Karyomegalic interstitial nephropathy (KIN) is a rare form of chronic tubulointerstitial nephritis, initially described as a familial nephropathy in adults. So far, four cases of KIN have been reported in pediatric and adolescent population following treatment with IFO. We report a 22-year-old man who developed renal dysfunction following IFO therapy for relapsed Hodgkin's lymphoma. Renal biopsy revealed chronic tubulointerstitial nephritis with atypical tubular epithelial cells showing nuclear enlargement and hyperchromasia, consistent with a diagnosis of KIN. The renal function improved following a short course of corticosteroids.

Keywords: Cancer chemotherapy; chronic interstitial nephritis; karyomegaly.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Light microscopy showing normal glomeruli with diffuse moderate degree of lymphocytic infiltration (H and E ×100); (b) H and E staining showing tubules with enlarged nuclei (H and E ×200); (c and d) PAS staining showing enlarged hyperchromatic nuclei in the tubules (PAS ×400)
See this image and copyright information in PMC

References

    1. Monga G, Banfi G, Salvadore M, Amatruda O, Bozzola C, Mazzucco G. Karyomegalic interstitial nephritis: Report of 3 new cases and review of the literature. Clin Nephrol. 2006;65:349–55. - PubMed
    1. McCulloch T, Prayle A, Lunn A, Watson AR. Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy. Pediatr Nephrol. 2011;26:1163–6. - PubMed
    1. Matsuura T, Wakino S, Yoshifuji A, Nakamura T, Tokuyama H, Hashiguchi A, et al. Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid. CEN Case Rep. 2014;3:226–31. - PMC - PubMed
    1. Palmer D, Lallu S, Matheson P, Bethwaite P, Tompson K. Karyomegalic interstitial nephritis: A pitfall in urine cytology. Diagn Cytopathol. 2007;35:179–82. - PubMed
    1. Zhou W, Otto EA, Cluckey A, Airik R, Hurd TW, Chaki M, et al. FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet. 2012;44:910–5. - PMC - PubMed

Publication types